Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.03 USD
Change Today -0.004 / -13.79%
Volume 65.0K
OMBP On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

181 West Boardwalk

Suite 202

Fort Collins, CO 80525

United States

Phone: 970-237-5178

Fax:

Omni Bio Pharmaceutical, Inc. operates as a biopharmaceutical company. The company focuses on exploring new methods of use of alpha-1 antitrypsin (AAT). AAT is a naturally occurring protein that is essential for normal liver and lung function and has been purified from human blood (p-AAT) to treat patients suffering from emphysema due to AAT-deficiency. The company holds licenses for method of use issued patent claims for the use of p-AAT in the treatment of diabetes, certain bacterial and viral diseases and cellular transplantation and graft rejection, which include reducing the risk of a non-organ transplant rejection, reducing the risk of developing graft versus host disease (GvHD) and for treating GvHD in patients who have received a cornea, bone marrow, stem cell or pancreatic islet cell transplant. In addition, the company holds licenses for method of use patent application claims for the use of p-AAT in the treatment of radiation protection and myocardial remodeling. The company also holds a license to an issued method of use patent owned by a privately-held company for the treatment of diabetes using p-AAT. In 2011, the company began funding research and development of a synthetic form of AAT (Fc-AAT). In 2013, the company chose a specific form of the Fc-AAT molecule as its lead molecule (Fc-AAT 2) and is placing it into preclinical development. License and Sponsored Research Agreements Fc-AAT: The company holds an exclusive license with Regents of the University of Colorado (RUC) covering patent applications covering composition of matter and methods of use for various Fc-AAT constructs. Bacterial Disorders: The company holds an exclusive license with RUC covering a patent and patent applications for the use of p-AAT in the treatment and/or prevention of certain bacterial disorders. The Bacterial License also includes patent applications covering composition of matter and methods of use for its Fc-AAT 2 construct. Viral Disorders: The company holds a license with RUC covering patents and patent applications for the use of p-AAT in the treatment and/or prevention of certain viral disorders. Cellular Transplantation: The company holds an exclusive license with RUC covering patent applications for the use of p-AAT in the treatment of cellular transplantation rejection and graft rejection. The company is pursuing patent rights under this license agreement for the treatment of cellular transplantation and graft rejection disorders, including GvHD, in the U.S., Canada, and Europe. Diabetes: The company holds a license to an issued patent for the treatment of diabetes (Types 1 and 2) using p-AAT (the Diabetes Patent) with Bio Holding, Inc. (Bio Holding). Research and Development As of March 31, 2014, the company incurred approximately $163,000, on research and development expenses.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMBP:US $0.03 USD -0.004

OMBP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMBP.
View Industry Companies
 

Industry Analysis

OMBP

Industry Average

Valuation OMBP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMNI BIO PHARMACEUTICAL INC, please visit www.omnibiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.